Disability

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

Staff September 9, 2025

GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been...

TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment

Staff September 8, 2025

Phase 3 trial to evaluate two subcutaneous BRIUMVI dosing regimensNEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc....

Tenon(R) Medical Announces Second Peer-Reviewed Catamaran Mainsail(TM) Study Publication, Underscores Robust and Sustainable Clinical Outcomes Out to 12 Months

Staff September 4, 2025

~ Clinically Significant Patient Outcomes Demonstrate Improvements in Pain (VAS) and Disability (ODI), Along with High Patient Satisfaction and Safety...

Sen. Debbie Stabenow, State Legislators to Highlight Annual Walk a Mile in My Shoes Rally & Warn Against State PIHP Procurement Process

Staff September 4, 2025

Stabenow, other state leaders to sound alarm against the competitive procurement process for prepaid inpatient health plansLANSING, Mich., Sept. 04,...

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

Staff September 1, 2025

Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded...

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

Staff September 1, 2025

ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis...

Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

Staff September 1, 2025

Illustrative image Laboratory, Boehringer Ingelheim This press release is not intended for UK and US media. HERNEXEOS® (zongertinib tablets) has been...

Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease

Staff August 31, 2025

Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke...

EndoUVTech Announces Strategic Partnership with CeramOptec to Advance UV Laser Stroke Therapy Toward FDA Submission

Staff August 24, 2025

OAKLAND PARK, FL / ACCESS Newswire / August 24, 2025 / EndoUVTech, a medical device innovator pioneering UV laser technology...

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

Staff August 20, 2025

WALTHAM, Mass. and DUBLIN and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage...

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

Staff August 20, 2025

WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage...

RethinkFirst Acquires Joshin to Create First Fully Integrated Neurodiversity and Disability Support Platform

Staff August 19, 2025

Combining intelligent tools and personalized support, RethinkCare empowers employers, families and caregivers with clinically validated resources, expert coaching and navigation...

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

Staff August 18, 2025

ENX-CL-05-001 Trial: 3-months topline data - In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including...

Enlyte Celebrates National Adjuster Day With Clinician-Reviewed Medical Records Tool to Ease Claims Burden

Staff August 14, 2025

Medical Records Summarization (MRS) for bodily injury claims integrates AI automation with expert analysis to hasten claims resolution SAN DIEGO,...

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain

Staff August 13, 2025

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on...

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain

Staff August 13, 2025

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on...

Chisholm Chisholm & Kilpatrick LTD and National Veterans Legal Services Program Challenge VA’s Denial of Benefits to Caregivers after Veterans’ Deaths

Staff August 13, 2025

Class Actions Seeks to Represent Untold Number of Caregivers Who Appealed Denials from the VA's Program of Comprehensive Assistance for...

Tango Belt by ActiveProtective Now Available in Select Regions; Sets New Standard in Fall Injury Mitigation

Staff August 12, 2025

CONSHOHOCKEN, Pa., Aug. 12, 2025 /PRNewswire/ -- ActiveProtective® is proud to announce the FDA-authorized breakthrough medical device the Tango® Belt...

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

Staff August 11, 2025

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology...

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

Staff August 11, 2025

– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment...

Disability

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment

Tenon(R) Medical Announces Second Peer-Reviewed Catamaran Mainsail(TM) Study Publication, Underscores Robust and Sustainable Clinical Outcomes Out to 12 Months

Sen. Debbie Stabenow, State Legislators to Highlight Annual Walk a Mile in My Shoes Rally & Warn Against State PIHP Procurement Process

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease

EndoUVTech Announces Strategic Partnership with CeramOptec to Advance UV Laser Stroke Therapy Toward FDA Submission

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

RethinkFirst Acquires Joshin to Create First Fully Integrated Neurodiversity and Disability Support Platform

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

Enlyte Celebrates National Adjuster Day With Clinician-Reviewed Medical Records Tool to Ease Claims Burden

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain

Chisholm Chisholm & Kilpatrick LTD and National Veterans Legal Services Program Challenge VA’s Denial of Benefits to Caregivers after Veterans’ Deaths

Tango Belt by ActiveProtective Now Available in Select Regions; Sets New Standard in Fall Injury Mitigation

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026

Best Ipamorelin vs Sermorelin: Growth Hormone Peptide Comparison 2026 — ReadyRx Prescription Telehealth Analysis

GLP-1 Booster From Health Journey: 2026 Ingredient Analysis And Probiotic Metabolic Support Explained

MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs

Best Peptides for Anti-Aging: NAD+ Delivery Methods Compared as Telehealth Platforms Expand Access (2026 Analysis)

You may have missed